What you carry at this position in your DNA and what research says about it.
Bone Strength: 7/10 evidence, 18 publications.
You're viewing every possible genotype for this variant.
None of these is your result. Use the genotype toggle to compare them, then sign up and upload your DNA to see which one is yours.
Sample genotype (not yours): A/A
Typical Bone Strength and Cardiovascular Risk
Two copies of the fully functional receptor gene maintain standard bone density and immune responses. This baseline function is associated with typical risks for osteoporosis and depression, alongside standard cardiovascular health.
What this genotype means: Typical bone mineral density; Standard risk of depression; Typical cardiovascular risk profile.
Sample genotype (not yours): A/C
One copy of the loss-of-function variant slightly reduces receptor activity. This intermediate state generally maintains typical bone density and standard cardiovascular risk.
What this genotype means: Slightly reduced receptor activity; Typical bone density; Standard cardiovascular risk.
Sample genotype (not yours): C/C
Weaker Bones but Lower Stroke Risk
Two copies of the loss-of-function variant result in a non-functional receptor. This state reduces systemic inflammation, lowering stroke risk, but increases the risk of osteoporosis and depression.
What this genotype means: Lower bone mineral density; Higher risk of osteoporosis and fractures; Reduced risk of ischemic stroke.
Gene function and biological role
Gene Function: The P2RX7 gene encodes the P2X7 receptor, an ATP-gated ion channel found on immune cells, microglia, and bone cells [1]. This receptor plays a critical role in regulating inflammation, immune responses, and bone remodeling [1]. When activated by extracellular ATP, the channel opens to allow the flow of ions and, under prolonged stimulation, forms a large pore that can trigger cell death [2]. It is highly polymorphic, with several genetic variations significantly altering its function [1].
Variant Impact: The rs3751143 variant is a missense mutation in the P2RX7 gene that changes the amino acid glutamic acid to alanine at position 496 of the protein [1]. This specific change impairs the proper assembly of the P2X7 receptor on the cell surface [1]. As a result, the receptor exhibits a severe loss of function, failing to open or form pores normally in response to ATP [1]. This reduction in receptor activity alters inflammatory signaling and bone metabolism [2].
Key Insight: A complete loss of P2X7 receptor function presents a biological trade-off, protecting the cardiovascular system by lowering inflammation while simultaneously weakening bone structure.
Location: P2RX7. Chromosome 12 · 12q24.31 · 121.2 Mb
Estimated prevalence by population
Global 71.1%; European 67.0%; African 82.2%; East Asian 55.0%; South Asian 50.6%; Americas 67.5%; Ashkenazi 64.4%; Finnish 80.7%; Middle Eastern 53.5%; Amish 67.8%.
Estimated AA genotype frequency.
Global 26.1%; European 29.7%; African 16.9%; East Asian 38.3%; South Asian 41.1%; Americas 29.3%; Ashkenazi 31.7%; Finnish 18.3%; Middle Eastern 39.3%; Amish 29.1%.
Estimated AC genotype frequency.
Global 2.8%; European 3.3%; African 0.9%; East Asian 6.7%; South Asian 8.3%; Americas 3.2%; Ashkenazi 3.9%; Finnish 1.0%; Middle Eastern 7.2%; Amish 3.1%.
Estimated CC genotype frequency.
Showing effects for A/A genotype
Organ Systems
Bone, Joint & Connective Tissue Health
Bone Strength. Evidence: 3/10. Source: PMID 22776862. Typical.
Neurology & Mental Health
Mood Disorders
Depression. Evidence: 7/10. Source: PMID 38177345. Typical.
Cardiovascular & Metabolic
Heart Disease
Cardiovascular Risk. Evidence: 3/10. Source: PMID 22662160. Typical.
Immunity & Inflammation
Inflammatory & Circulating Protein Markers
C-Reactive Protein. Evidence: 7/10. Source: PMID 31900758. Typical.
Showing effects for A/C genotype
Showing effects for C/C genotype
Bone Strength. Evidence: 3/10. Source: PMID 22776862. Lower Density.
Depression. Evidence: 7/10. Source: PMID 38177345. Higher Risk.
Cardiovascular Risk. Evidence: 3/10. Source: PMID 22662160. Lower Risk.
C-Reactive Protein. Evidence: 7/10. Source: PMID 31900758. Lower Levels.
What this genotype means for the people who carry it
Sample genotype: AA (Homozygous)
Standard receptor activity ensures normal bone remodeling and inflammatory signaling [1]. This typical function is associated with a baseline risk of developing osteoporosis and experiencing bone fractures [2]. It also maintains standard susceptibility to mood disorders like major depression [3]. However, fully active receptors can promote inflammatory pathways that slightly elevate the risk of cardiovascular events compared to those with reduced receptor function [4]. C-reactive protein levels, a key marker of systemic inflammation, tend to be typical or slightly higher in this group [5].
Typical bone mineral density; Standard risk of depression; Typical cardiovascular risk profile.
Sample genotype: AC (Heterozygous)
Carrying one copy of the altered gene leads to a moderate reduction in receptor assembly and function [1]. This partial loss of activity is usually not enough to significantly alter bone mineral density or fracture risk under normal conditions [2]. Susceptibility to depression and other mood disorders remains close to the population average [3]. Similarly, the slight reduction in inflammatory signaling provides only a minor, non-significant shift in cardiovascular risk [4]. Systemic inflammation markers like C-reactive protein are typically within the normal range [5].
Slightly reduced receptor activity; Typical bone density; Standard cardiovascular risk.
Sample genotype: CC (Homozygous)
Complete loss of receptor function significantly alters both bone metabolism and inflammatory pathways [1]. The lack of active receptors impairs bone remodeling, leading to lower bone mineral density and a higher risk of osteoporosis and fractures [2]. In the brain, altered microglial and inflammatory signaling is linked to an increased susceptibility to major depressive disorder [3]. Conversely, the dramatic reduction in systemic inflammation offers a protective effect against cardiovascular diseases [4]. This includes a significantly lower risk of ischemic stroke and ischemic heart disease, particularly in individuals with hypertension or who smoke [4]. C-reactive protein levels are also typically lower, reflecting reduced baseline inflammation [5].
Lower bone mineral density; Higher risk of osteoporosis and fractures; Reduced risk of ischemic stroke; Higher risk of major depression.
Variants with shared genetic architecture
rs28360457 · P2RX7 Gene · Chr 12 · Inflammation and Bone Health
rs1718119 · P2RX7 Gene · Chr 12 · Inflammatory and Bone Health
rs208294 · P2RX7 Gene · Chr 12 · Mood and Pain Sensitivity
Genetics of the P2X7 receptor and human disease.
Association of purinergic receptor P2RX7 gene polymorphisms with depression symptoms.
Content updated August 2026.
ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.
Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026
Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com